GSK Acquires Nuvalent to Expand Oncology Pipeline | Lucid Diligence Brief
GSK strengthens its oncology portfolio with Nuvalent acquisition, adding…
Secretome STM-01 Duchenne Cardiomyopathy | Lucid Diligence Brief
Secretome’s STM-01 faces Duchenne cardiomyopathy endpoint, CMC, and regulatory…
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay
Lucid Diligence Brief: AstraZeneca Camizestrant FDA Delay Raises SERENA-6…
Lucid Diligence Brief: SELLAS REGAL AML Phase 3 Nears Final Analysis
Lucid Diligence Brief: SELLAS approaches REGAL AML final analysis for…
Lucid Diligence Brief: Cullinan Therapeutics Gains FDA Orphan Drug Designation for CLN-049
Lucid Diligence Brief: Cullinan Therapeutics Receives FDA Orphan Drug…
Lucid Diligence Brief: Endologix's Pounce Acquisition
Lucid Diligence Brief: Endologix’s Pounce acquisition framed through clinical,…
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition
Lucid Diligence Brief: NeuroVision’s Durin Life Sciences acquisition…
Lucid Diligence Brief: Axoft $55 million Series A
Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…
Lucid Diligence Brief: Teva to acquire Emalex Biosciences
Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on AI-powered subdural hemorrhage care
Lucid Diligence Brief: Viz.ai and Johnson & Johnson collaboration on…
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership
Lucid Diligence Brief: CellCarta and Pillar Biosciences strategic partnership…
Hematology Today—March 23, 2026
This week’s Hematology update highlights hemophilia gene therapy supply…
